Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 7/20 | 0.69 |
| ▸ | DRD2 | P14416 | 3/20 | 0.61 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.57 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.55 |
| ▸ | THRB | P10828 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12311974 | 0.87 | DRD3 (0.70) | DRD3DRD2CYP4F2CYP4A11KCNA5 | |
| SCHEMBL17197060 | 0.83 | DRD3 (0.77) | DRD3DRD2CYP4F2CYP4A11KCNA5 | |
| SCHEMBL23640213 | 0.83 | MEN1 (0.58) | DRD3DRD2KCNA5HRH3KDM4E | |
| SCHEMBL13091445 | 0.81 | KDM4E (0.71) | HRH3KDM4EALDH1A1MEN1HTT | |
| SCHEMBL13056677 | 0.78 | DRD3 (0.73) | DRD3DRD2CYP4F2CYP4A11KCNA5 | |
| SCHEMBL23640243 | 0.78 | HRH3 (0.53) | DRD3DRD2KCNA5HRH3KDM4E | |
| SCHEMBL10200150 | 0.78 | DRD3 (0.68) | DRD3DRD2CYP4F2CYP4A11KCNA5 | |
| SCHEMBL23640249 | 0.77 | LTA4H (0.56) | DRD3DRD2KCNA5HRH3KDM4E | |
| SCHEMBL259795 | 0.77 | NPC1 (0.77) | HRH3RAB9AKDM4ESIGMAR1ALDH1A1 | |
| SCHEMBL18837292 | 0.77 | DRD3 (0.67) | DRD3DRD2CYP4F2CYP4A11HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3848367-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CRBN, CSNK2A1, CSNK2A2 | DRD3 4339/4885DRD2 4621/4885CYP4F2 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.